What question did this study set out to answer?

To compare the antihypertensive efficacy and tolerability of once-daily moxonidine (0.6 mg) with enalapril (20 mg) and placebo in patients with mild to moderate essential hypertension.

January 1, 2002Blood PressureOpen Access

Placebo-controlled Comparison of the Efficacy and Tolerability of Once-daily Moxonidine and Enalapril in Mild to Moderate Essential Hypertension

View Full Paper

Ask AI

Bookmark

Why the study?

Does moxonidine reduce blood pressure compared to enalapril and placebo in patients with mild to moderate essential hypertension?

Key Points

To compare the antihypertensive efficacy and tolerability of once-daily moxonidine (0.6 mg) with enalapril (20 mg) and placebo in patients with mild to moderate essential hypertension.
Randomized 154 patients to receive placebo (n = 50), moxonidine (0.2 mg once daily; n = 51), or enalapril (5 mg once daily; n = 53) for 2 weeks, followed by dose titration to moxonidine 0.6 mg or enalapril 20 mg for an additional 6 weeks.
Measured blood pressure responses across the 8-week treatment period using conventional office techniques and 24-hour ambulatory blood pressure monitoring.
Sitting blood pressure was reduced by 24.9 ± 20.7 / 13.2 ± 8.4 mmHg with moxonidine (from 166.2 ± 15.5 / 101.3 ± 4.0 to 141.2 ± 15.7 / 88.1 ± 7.7 mmHg) and 21.9 ± 17.1 / 11.9 ± 7.5 mmHg with enalapril (from 165.4 ± 14.3 / 101.1 ± 4.4 to 143.5 ± 12.7 / 89.2 ± 7.4 mmHg), both significantly superior to placebo at 1.2 ± 14.4 / 2.3 ± 7.0 mmHg (p < 0.001).
Average 24-hour blood pressure decreased from 149.8 ± 14.3 / 92.2 ± 7.0 to 134.0 ± 13.1 / 82.3 ± 8.9 mmHg with moxonidine and from 146.5 ± 13.0 / 92.5 ± 7.2 to 131.1 ± 11.0 / 82.1 ± 8.8 mmHg with enalapril (p < 0.01 for overall effect of either drug vs placebo: 147.3 ± 13.3 / 90.0 ± 6.2 to 144.8 ± 12.9 / 89.5 ± 8.0 mmHg).
Both active medications were well tolerated, with no patients withdrawing from the trial due to drug-attributed adverse events.

Structured PICO

Does moxonidine reduce blood pressure compared to enalapril and placebo in patients with mild to moderate essential hypertension?

Population

154 patients with mild to moderate essential hypertension

Intervention

Moxonidine 0.2 mg once daily for 2 weeks, then increased to 0.6 mg once daily for 6 weeks

Comparator

Enalapril 5 mg once daily for 2 weeks, then increased to 20 mg once daily for 6 weeks, and placebo

Outcome

Blood pressure responses measured using conventional office techniques and 24-h ambulatory blood pressure monitoringsurrogate

Moxonidine 0.6 mg once daily provides similar antihypertensive efficacy to enalapril 20 mg once daily in patients with mild to moderate essential hypertension.

Authors

BPBrian N. C. PrichardUniversity College Hospital BJB JägerSolvay (Belgium)JLJoachim LuszickSolvay (Germany)

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Moxonidine matches enalapril as an alternative for mild-moderate hypertension; confirms efficacy of this centrally acting agent versus ACE inhibitors and placebo.

Cite This Study

Prichard et al. (2002) studied this question.

synapsesocial.com/papers/6a7ba5e7a540d02696c28e1b https://doi.org/10.1080/080370502760050403

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

Moxonidine matches enalapril as an alternative for mild-moderate hypertension; confirms efficacy of this centrally acting agent versus ACE inhibitors and placebo.

Placebo-controlled Comparison of the Efficacy and Tolerability of Once-daily Moxonidine and Enalapril in Mild to Moderate Essential Hypertension

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Placebo-controlled Comparison of the Efficacy and Tolerability of Once-daily Moxonidine and Enalapril in Mild to Moderate Essential Hypertension

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider